Initiator Pharma A/S (INIT) AI Stock Analysis

0 Followers

Initiator Pharma A/S

(Nasdaq OMX AB:INIT)

Select Model

Rating:46Neutral

Price Target:SEK 2.00▲(10.80% Upside)

Action:reiterated

Date:10/25/26

The score is driven primarily by weak financial performance: no revenue, accelerating losses, heavy cash burn, and a materially weakened balance sheet (equity down sharply while debt increased), all of which heighten funding and dilution risk. Technicals provide some near-term support (price above 20DMA, positive MACD), but the stock remains below longer-term moving averages. Valuation is constrained by ongoing losses (negative P/E) and no indicated dividend yield.

Positive Factors

Focused Clinical PipelineA clearly defined lead program gives Initiator Pharma a focused development strategy rather than a broad, diffuse pipeline. Concentrating resources on pudafensinil may support disciplined capital allocation and create a coherent path toward clinical validation if the candidate demonstrates sufficient efficacy and safety.

Negative Factors

No Commercial RevenueNo revenue means Initiator Pharma has not yet established a commercial funding engine and remains dependent on capital markets or other external financing. This leaves future development spending exposed to financing conditions and makes progress toward commercialization especially important for business durability.

Initiator Pharma A/S (INIT) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 123.90M
Dividend Yield: ―
Average Volume (3M): 141.57K
Price to Earnings (P/E): -3.1
Beta (1Y): 0.54
Revenue Growth: ―
EPS Growth: -111.93%
Country: Sweden
Employees: 1
Sector: General
Sector Strength: 55
Industry: Biotechnology

Initiator Pharma A/S Business Overview & Revenue Model

Company Description

Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase...

Initiator Pharma A/S Financial Statement Overview

Summary

Pre-revenue profile with widening losses (TTM net income -27.9m vs -14.0m in 2025) and worsening cash burn (TTM FCF -23.7m vs -17.7m). Balance sheet flexibility has weakened as equity fell sharply (8.5m vs 29.6m) while debt rose to 9.7m, increasing refinancing/dilution risk.

Income Statement

9Very Negative

Balance Sheet

28Negative

Cash Flow

14Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	-29.73M	-14.83M	-11.07K	-23.41K	-38.42K	-21.63K
EBITDA	-31.99M	-18.20M	-14.50K	-27.03K	-41.73K	-12.07K
Net Income	-28.00M	-14.01M	-12.93K	-22.87K	-38.45M	-21.06M
Balance Sheet
Total Assets	20.94M	32.99M	15.29M	29.79M	48.34M	53.70M
Cash, Cash Equivalents and Short-Term Investments	17.10M	26.26M	13.37M	24.34M	38.91M	34.15M
Total Debt	9.69M	2.15M	0	15.44M	12.58M	13.29M
Total Liabilities	12.41M	3.43M	510.00K	18.62M	14.32M	18.71M
Stockholders Equity	8.53M	29.56M	14.78M	11.16M	34.02M	34.99M
Cash Flow
Free Cash Flow	-23.70M	-17.73M	-12.08M	-17.65M	-32.70M	-34.10M
Operating Cash Flow	-23.47M	-18.19M	-12.08M	-17.65M	-32.70M	-34.10M
Investing Cash Flow	0	0	0	0	-17.00K	0
Financing Cash Flow	35.76M	31.36M	1.11M	2.87M	37.48M	54.94M

Initiator Pharma A/S Technical Analysis

Technical Analysis SentimentNegative

Last Price1.80

Price Trends

50DMA2.17Negative

100DMA2.37Negative

200DMA2.71Negative

Market Momentum

MACD-0.03Positive

RSI37.35Neutral

STOCH29.89Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INIT, the sentiment is Negative. The current price of 1.80 is below the 20-day moving average (MA) of 2.06, below the 50-day MA of 2.17, and below the 200-day MA of 2.71, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 37.35 is Neutral, neither overbought nor oversold. The STOCH value of 29.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:INIT.

Initiator Pharma A/S Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SE:INIT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:ELIC	48Neutral	SEK 178.19M	-7.39	-56.09%	―	―	14.10%
SE:NXTCL	46Neutral	SEK 32.04M	-0.75	-81.23%	―	-4.02%	35.86%
SE:INIT	46Neutral	SEK 123.90M	-3.06	―	―	―	-111.93%
SE:ALZ	43Neutral	SEK 108.25M	-1.59	-17.52%	―	-100.00%	20.94%
SE:ACTI	42Neutral	SEK 105.44M	-10.41	-93.01%	―	―	54.60%
SE:XINT	39Underperform	SEK 133.50M	-2.51	245.07%	―	-38.46%	9.02%

* General Sector Average

Performance Comparison

SE:INIT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:INIT	Initiator Pharma A/S	1.80	-1.22	-40.43%
SE:ALZ	Alzinova AB	0.34	-1.03	-75.37%
SE:XINT	Xintela AB	0.15	-0.23	-60.70%
SE:ELIC	Elicera Therapeutics AB	2.62	-3.19	-54.97%
SE:ACTI	Active Biotech AB	4.10	-2.18	-34.67%
SE:NXTCL	NextCell Pharma AB	0.29	-0.55	-65.99%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 25, 2026

Initiator Pharma A/S AI Stock Analysis